Clinical Trial Update: A Phase III Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg Plus Acarbose 50 mg Tablets) Versus Acarbose Alone in Subjects With Type 2 Diabetes Mellitus [Phase 3]

View source ↗

Summary

Phase III randomized trial comparing Acarmet (metformin HCl 500 mg plus acarbose 50 mg) thrice daily versus acarbose 50 mg thrice daily in subjects with Type 2 …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Acarbose (acarbose)
• Acarmet (metformin HCl 500 mg + acarbose 50 mg)

Snippet

Sponsor: Lotus Pharmaceutical | Conditions: The Objectives of the Study is to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg, Plus Acarbose 50 mg Tablets) Thrice Daily Versus Acarbose 50 mg Thrice Daily Over 16 Weeks in | Phase 3 | Status: UNKNOWN